Gland Pharma Ltd. (GLAND) Share Price Hits Fresh 52-Week High at Rs 2,929.65

Gland Pharma Ltd. Share Price stood at Rs 2,872, up 7.83% today after hitting a fresh 52-week high of Rs 2,929.65. Market capitalisation: Rs 42,898.76 crore.

Gland Pharma Ltd. Share Price is in focus after the stock rose to Rs 2,872 on 11 August 2026, up Rs 208.5 or 7.83% from the previous close of Rs 2,663.5, and touched a fresh 52-week high of Rs 2,929.65. With a market capitalisation of Rs 42,898.76 crore, the move has placed the company among the notable Healthcare names being watched in Stock Market Today and Share Market Today discussions.

The verified data confirms a sharp price event: Gland Pharma Ltd. Share Price opened at Rs 2,837.55, traded between Rs 2,830.35 and Rs 2,929.65, and generated turnover of Rs 10.04 crore on volume of 34,951 shares. That combination makes this Gland Pharma Ltd. Stock News event relevant because it signals a fresh one-year high backed by active trading, even though the supplied data does not establish a company-specific catalyst.

For investors tracking Gland Pharma Ltd. Share Price Today, the important takeaways are clear within the first few minutes of analysis. What happened today? The stock hit a new yearly high. Why is it trending? The verified data shows a strong day move and a 52-week peak. What financial metrics matter here? Market cap is Rs 42,898.76 crore, P/E is 40.09, P/B is 9.77, ROE is 28.21, and ROCE is 26.35. What should investors monitor next? Price behaviour around the new high, valuation versus the Healthcare benchmark, and how the stock compares with listed peers. Univest sees this as a data-led event worth tracking, not a call on direction.

Gland Pharma Ltd. Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 2,872
Previous Close	Rs 2,663.5
Today's Change	+Rs 208.5 (+7.83%)
Day Open	Rs 2,837.55
Fresh 52-Week High	Rs 2,929.65
Day Low	Rs 2,830.35
Current Volume	34,951
Turnover	Rs 10.04 crore
Market Capitalisation	Rs 42,898.76 crore

Gland Pharma Ltd. (GLAND) traded at Rs 2,872. versus the previous close of Rs 2,663.5, a rise of 7.83%. The stock opened at Rs 2,837.55, reached Rs 2,929.65, touched Rs 2,830.35. Reported volume was 34,951.

Gland Pharma Ltd. Share Price Today reflects a strong session so far, with the stock rising 7.83%, opening firm, holding above the previous close, and printing a fresh 52-week high at Rs 2,929.65. The move puts the stock on the market radar as a one-year high candidate backed by measurable turnover and intraday range expansion.

At the time captured in the supplied data, Gland Pharma Ltd. Share Price was Rs 2,872 versus a previous close of Rs 2,663.5, a gain of Rs 208.5. The stock opened at Rs 2,837.55, which already placed it above the previous close, and then moved to an intraday high of Rs 2,929.65 while the day low stood at Rs 2,830.35. That range shows the stock stayed well above the earlier close throughout the captured session.

Turnover came in at Rs 10.04 crore on 34,951 shares. For traders and long-term trackers alike, that matters because a fresh 52-week peak accompanied by active traded value tends to attract more attention than a thin move. In Market News terms, this places Gland Pharma Ltd. Share Price among the Healthcare names generating a meaningful Share Price Update rather than a marginal tick higher.

This also shapes the answer to a common search query: Why Is Gland Pharma Ltd. Rising Today? Based on the supplied data, the confirmed reason is the price event itself. The stock has gained sharply, stayed above the previous close, and reached a new 52-week high. The supplied figures verify the move, while the next step is to examine whether the fundamental backdrop supports this level of investor attention.

Gland Pharma Ltd. (GLAND) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 42,898.76 crore
P/E Ratio	40.09x
P/B Ratio	9.77x
ROE	28.21%
ROCE	26.35%

Gland Pharma Ltd. was valued at a P/E ratio of 40.09x, a P/B ratio of 9.77x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 28.21% and ROCE of 26.35%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Company P/E Ratio	40.09x
Benchmark Median P/E	20.84x
Benchmark Average P/E	76.55x
Benchmark P/E Range	0x to 3,396.3x
Company P/B Ratio	9.77x
Benchmark Median P/B	1.93x
Company ROE	28.21%
Benchmark Median ROE	10.77%
Company ROCE	26.35%
Benchmark Median ROCE	13.35%
Company Market Capitalisation	Rs 42,898.76 crore
Benchmark Median Market Cap	Rs 142.3 crore

Gland Pharma Ltd. (GLAND) is classified under sector: Healthcare.

Gland Pharma Ltd. (GLAND) has a P/E ratio of 40.09x, which is above the benchmark median of 20.84x, a difference of +92.37%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Gland Pharma Ltd. (GLAND) has a ROE of 28.21%, which is above the benchmark median of 10.77%, a difference of +161.93%. Gland Pharma Ltd. (GLAND) has a ROCE of 26.35%, which is above the benchmark median of 13.35%, a difference of +97.38%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Kwality Pharmaceuticals Ltd.	KPL	2,707.2	40.09	9.77	28.21	26.35
Beta Drugs Ltd.	BETA	2,631.45	66.92	10.59	18.65	22.17
Dr Agarwals Eye Hospital Ltd.	DRAGARWQ	2,601.85	34.14	7.04	-2.6	16.92
Sai Parenteral's Ltd.	SAIPARENT	2,513.58	181.97	3.36	13.9	12.97
NGL Fine-Chem Ltd.	NGLFINE	2,118.6	44.48	6.5	27.9	33.91

Gland Pharma Ltd. (GLAND) has a P/E ratio of 40.09x compared with the displayed peer median of 44.48x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 28.21% compares with a peer median of 18.65% across the companies shown in the table. ROCE stood at 26.35% versus the displayed peer median of 22.17%, providing a capital-efficiency comparison. Gland Pharma Ltd. (GLAND) has a market capitalisation of Rs 42,898.76 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

Why Investors Are Watching Gland Pharma Ltd.

Investors are watching Gland Pharma Ltd. Share Price because the stock has combined a sharp single-day gain with a fresh 52-week high, while the underlying metrics show strong return ratios and a clear valuation premium versus parts of the Healthcare benchmark.

• Fresh price trigger: Gland Pharma Ltd. Share Price rose 7.83% to Rs 2,872 and touched a new 52-week high of Rs 2,929.65.
• Intraday strength: The stock opened at Rs 2,837.55, stayed above the previous close of Rs 2,663.5, and traded with turnover of Rs 10.04 crore.
• Fundamental context: Market cap is Rs 42,898.76 crore, P/E is 40.09, P/B is 9.77, ROE is 28.21, and ROCE is 26.35.
• Sector positioning: ROE and ROCE are above the Healthcare sector median and average, while P/E and P/B are above the sector median.
• Peer lens: Relative to supplied peers, profitability compares well, while valuation sits within a broad but premium range.

About Gland Pharma Ltd.

Gland Pharma Ltd. operates in the Healthcare sector. In the supplied comparison data, the company is grouped against businesses in Healthcare and, across the peer set, largely alongside Pharmaceuticals & Drugs companies, with one Hospital & Healthcare Services peer also included. That places Gland Pharma in a segment of the market where investors often compare valuation, scale and capital efficiency across a broad set of healthcare businesses.

From a market-position perspective, Gland Pharma stands out in the current dataset for its size. Its market capitalisation of Rs 42,898.76 crore is substantially above the peer sample, which ranges between Rs 2,118.6 crore and Rs 2,707.2 crore, and also far above the same-sector benchmark median of Rs 142.3 crore and average of Rs 472.15 crore. That makes Gland Pharma Ltd. Share Price relevant not only for daily traders looking at 52 Week High Stocks, but also for investors monitoring larger Healthcare names within the Indian Stock Market. On Univest, that combination of scale, profitability and current price momentum is why the stock is drawing attention in today’s Stock Updates.

Track Gland Pharma Ltd. Share Price on Univest

Use Gland Pharma Ltd. (GLAND) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

Investors following Gland Pharma Ltd. Share Price can track live Share Price moves, 52-week levels, market capitalisation, valuation ratios, profitability metrics and broader stock analysis on Univest. For readers searching Gland Pharma Ltd. Share Price Live, Gland Pharma Ltd. Latest News or Gland Pharma Ltd. Shareholding Pattern updates, Univest brings the verified market data into one place for easier monitoring.

As this fresh one-year high shows, price action alone can put a stock into focus. But a fuller view usually comes from combining price, valuation, peer context and sector data. Univest helps users track those layers together so that Gland Pharma Ltd. Share Price Today is seen in context rather than in isolation.

Frequently Asked Questions

What is Gland Pharma Ltd. Share Price today?

Ans. Gland Pharma Ltd. Share Price was Rs 2,872 in the supplied market snapshot. The stock was up Rs 208.5, or 7.83%, from the previous close of Rs 2,663.5, placing it among notable Healthcare stocks in news today.

What fresh 52-week high did Gland Pharma Ltd. hit?

Ans. Gland Pharma Ltd. Share Price touched a fresh 52-week high of Rs 2,929.65. The stock later traded at Rs 2,872, showing that it remained elevated even after the intraday peak recorded in the supplied data.

Why is Gland Pharma Ltd. Share Price rising today?

Ans. The verified data confirms a sharp market move: Gland Pharma Ltd. Share Price rose 7.83%, opened at Rs 2,837.55 and reached a new one-year high of Rs 2,929.65. The supplied figures confirm the event but do not identify a company-specific.

How much market capitalisation does Gland Pharma Ltd. have?

Ans. Gland Pharma Ltd. had a market capitalisation of Rs 42,898.76 crore in the supplied snapshot. That is far above the same-sector benchmark median of Rs 142.3 crore and average of Rs 472.15 crore, highlighting the company’s large scale.

What do the valuation ratios of Gland Pharma Ltd. show?

Ans. Gland Pharma Ltd. trades at a P/E ratio of 40.09 and a P/B ratio of 9.77. Those figures are above the Healthcare sector median values of 20.84 for P/E and 1.93 for P/B in the supplied benchmark.

How profitable is Gland Pharma Ltd. based on ROE and ROCE?

Ans. Gland Pharma Ltd. reported ROE of 28.21 and ROCE of 26.35 in the supplied data. Both measures are above the Healthcare sector median of 10.77 for ROE and 13.35 for ROCE, indicating strong return ratios.

How did Gland Pharma Ltd. trade during the session?

Ans. Gland Pharma Ltd. Share Price opened at Rs 2,837.55, hit a day high of Rs 2,929.65 and a day low of Rs 2,830.35. The stock remained above the previous close of Rs 2,663.5 throughout that captured trading range.

What was the trading volume and turnover in Gland Pharma Ltd.?

Ans. The supplied data shows current volume of 34,951 shares in Gland Pharma Ltd. with turnover of Rs 10.04 crore. That combination suggests the fresh 52-week high was accompanied by measurable participation, not just a marginal price move.

How does Gland Pharma Ltd. compare with the Healthcare sector benchmark?

Ans. Versus the same-sector benchmark of 197 companies, Gland Pharma Ltd. has higher profitability and richer valuation on several metrics. Its ROE and ROCE exceed sector medians, while its P/E and P/B also stand above the benchmark medians.

How does Gland Pharma Ltd. compare with selected peers?

Ans. Compared with supplied peers such as Beta Drugs, NGL Fine-Chem, Sai Parenteral's and Dr Agarwals Eye Hospital, Gland Pharma Ltd. shows competitive ROE and ROCE, while its P/E of 40.09 sits within a broad peer valuation range.